Nura Bio Initiates Phase I Clinical Trial for its Oral, Brain-Penetrant SARM1 Inhibitor, NB-4746 Portfolio News / By Karina Tin August 25, 2023 Nura Bio Initiates Phase I Clinical Trial for its Oral, Brain-Penetrant SARM1 Inhibitor, NB-4746 Read More »
RAPT Therapeutics Reports Second Quarter 2023 Financial Results Portfolio News / By Karina Tin August 11, 2023 RAPT Therapeutics Reports Second Quarter 2023 Financial Results Read More »
ORIC Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates Portfolio News / By Karina Tin August 10, 2023 ORIC Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates Read More »
Surrozen Provides Second Quarter 2023 Financial Results Portfolio News / By Karina Tin August 9, 2023 Surrozen Provides Second Quarter 2023 Financial Results Read More »
Tenaya Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update Portfolio News / By Karina Tin August 9, 2023 Tenaya Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update Read More »
Revolution Medicines Reports Second Quarter 2023 Financial Results and Update on Corporate Progress Portfolio News / By Karina Tin August 8, 2023 Revolution Medicines Reports Second Quarter 2023 Financial Results and Update on Corporate Progress Read More »
eFFECTOR Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update Portfolio News / By Karina Tin August 8, 2023 eFFECTOR Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update Read More »
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Portfolio News / By Karina Tin August 4, 2023 ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Read More »
NGM Bio Reports Second Quarter 2023 Financial Results and Provides Business Highlights Portfolio News / By Karina Tin August 3, 2023 NGM Bio Reports Second Quarter 2023 Financial Results and Provides Business Highlights Read More »
Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital Portfolio News / By Karina Tin August 1, 2023 Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital Read More »
